Download PDF
Semin Thromb Hemost 2006; 32(4): 437-442
DOI: 10.1055/s-2006-942765
Copyright © 2006 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Treatment of Polycythemia Vera

Richard T. Silver1
  • 1Division of Hematology-Oncology, New York Presbyterian-Weill Cornell Medical Center, New York, New York
Further Information

Publication History

Publication Date:
29 June 2006 (online)

    Permissions and Reprints

ABSTRACT

The selection of treatment for patients with polycythemia vera (PV) still is the subject of much discussion among hematologists. It is emphasized that important physiologic and pathogenic components of the illness relate not only to the erythroid cell, but also to the megakaryocyte. Both play essential roles in causing complications of the disease. Hematologists agree that the mainstay in treatment remains phlebotomy, a basic pillar of the concept of primum non nocere. In general, the target levels for the hematocrit have been accepted as ≤ 45% for men and ≤ 42% for women. Low-dose aspirin, 80 to 100 mg daily, should be used as a basic component of therapy. The selection of the type of treatment for those patients who require some form of myelosuppression owing to the frequency of phlebotomy and/or its complications provides the basis for major discussion, confrontation, and disagreement. For the most part, alkylating agents are avoided owing to the established risk of secondary leukemia, but these drugs and radioactive phosphorous (32P) still play a role in treating the very elderly patient or for those who have significant comorbid conditions. Whereas hydroxyurea remains the most frequently prescribed drug, limitations to its use as a therapeutic agent of choice include questions regarding its effectiveness, toxicity, and potential leukemogenicity. Interferon offers a rational choice of treatment owing to its broad physiologic effects on hematopoiesis. Whereas its effect in treating patients with PV is unequivocal, it is associated with side effects even when used properly. Moreover, it has only modest effect on Janus kinase 2 (JAK2) expression. Clearly, the best treatment for patients with PV is still sought. Perhaps more explicit exploitation of the JAK2 abnormality found in PV (and other myeloproliferative diseases) may provide more effective agents in the future.

KEYWORDS

Polycythemia vera - phlebotomy - aspirin - hydroxyurea - JAK2 - interferon - radioactive phosphorus

REFERENCES

  • 1 Messinezy M, Pearson T C, Pochazka A et al.. Treatment of primary proliferative polycythemia by venisection and low-dose busulphan. Retrospective study from one centre.  Br J Haematol. 1985;  61 657-666
    PubMedGoogle Scholar
  • 2 Pearson T C, Wetherley-Mein G. Vascular occlusive episodes and venous hematocrit in primary proliferative polycythaemia.  Lancet. 1978;  2 1219-1222
    PubMedGoogle Scholar
  • 3 Berlin N I. Diagnosis and classification of the polycythemias.  Semin Hematol. 1975;  12 339-351
    PubMedGoogle Scholar
  • 4 Marchioli R, Finazzi G, Landolfi R et al.. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.  J Clin Oncol. 2005;  10 2224-2232
    PubMedGoogle Scholar
  • 5 Tefferri A, Spivak J L. Polycythemia vera: scientific advances and current practice.  Semin Hematol. 2005;  42(4) 206-220
    CrossrefPubMedGoogle Scholar
  • 6 Silver R T. Long-term results in the treatment of polycythemia vera with interferon.  Cancer. 2006;  , In press
    PubMedGoogle Scholar
  • 7 Michiels J J, Abels J, Steketee J et al.. Erythromelalgia caused by platelet-mediated arteriolar inflammation and thrombosis in thrombocythemia.  Ann Intern Med. 1985;  102 466-471
    PubMedGoogle Scholar
  • 8 Landolfi R, Marchioli R, Kutti J et al.. Efficacy and safety of low-dose aspirin in polycythemia vera.  N Engl J Med. 2004;  350(2) 114-124
    CrossrefPubMedGoogle Scholar
  • 9 Berk P D, Wasserman L R, Fruchtman S M et al.. Treatment of polycythemia vera: a summary of clinical trials conducted by the Polycythemia Vera Study Group. In: Wasserman LR, Berk PD, Berlin N Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia; WB Saunders 1995: 166-194
    Google Scholar
  • 10 Kaplan M E, Mack K, Goldberg J B et al.. Long term management of polycythemia vera with hydroxyurea: a progress report.  Semin Hematol. 1986;  23 167-171
    PubMedGoogle Scholar
  • 11 Marchioli R, Finazzi G, Landolfi R et al.. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.  J Clin Oncol. 2005;  10 2224-2232
    PubMedGoogle Scholar
  • 12 Nand S, Messmore H, Fisher S G et al.. Leukemia transformation in polycythemia vera: analysis of risk factors.  Am J Hematol. 1990;  34 32-36
    PubMedGoogle Scholar
  • 13 Weinfeld A, Swolin B, Westin J. Acute leukemia after hydroxyurea therapy in polycythemia vera and allied disorders: Prospective study of efficacy and leukaemogenicity with thererapeutic implications.  Eur J Haematol. 1994;  52 134-139
    PubMedGoogle Scholar
  • 14 Najean Y, Rain J D. Treatment of polycythemia vera-the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years.  Blood. 1997;  90 3370-3377
    PubMedGoogle Scholar
  • 15 Kaung D T, Swartzendruber A A. Effect of chemotherapeutic agents on chromosomes of patients with lung cancer.  Dis Chest. 1969;  55 98-100
    PubMedGoogle Scholar
  • 16 Landaw S A. Acute leukemia in polycythemia vera. In: Wasserman LR, Berk PD, Berlin N Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia; WB Saunders 1995: 154-165
    Google Scholar
  • 17 Silver R T. Recombinant interferon-alpha for treatment of polycythemia vera.  Lancet. 1988;  2 403
    PubMedGoogle Scholar
  • 18 Silver R T. A new treatment for polycythemia vera: recombinant interferon alfa.  Blood. 1990;  76 664-665
    PubMedGoogle Scholar
  • 19 Silver R T. Interferon-a2b: a new treatment for polycythemia vera.  Ann Intern Med. 1993;  119 1091-1092
    PubMedGoogle Scholar
  • 20 Silver R. Interferon alpha: effects of long-term treatment for polycythemia vera.  Semin Hematol. 1997;  34 40-50
    PubMedGoogle Scholar
  • 21 Lengfelder E, Berger U, Hehlmann R. Interferon in the treatment of polycythemia vera.  Ann Hematol. 2000;  79 103-109
    CrossrefPubMedGoogle Scholar
  • 22 Sacchi S, Leoni P, Liberati M et al.. A respective comparison between treatment with phlebotomy alone and with interferon alpha in patients with polycythemia vera.  Ann Hematol. 1994;  68 247-250
    CrossrefPubMedGoogle Scholar
  • 23 Taylor P C, Dolan G, Ng J P et al.. Efficacy of recombinant interferon-alpha (rIFN-a) in polycythemia vera: a study of 17 patients and an analysis of published data.  Br J Haematol. 1996;  92 55-59
    CrossrefPubMedGoogle Scholar
  • 24 Hino M, Futami E, Okuno S et al.. Possible selective effects of interferona-2b on a malignant clone in a case of polycythemia vera.  Ann Hematol. 1993;  66 161-162
    CrossrefPubMedGoogle Scholar
  • 25 Messora C, Be Qsi L, Vecchi A et al.. Cytogenetic conversion in a case of polycythemia vera treated with interferon-alpha.  Br J Haematol. 1994;  86 402-404
    PubMedGoogle Scholar
  • 26 Means R T, Krantz S B. Inhibition of human erythroid colony-forming units can be corrected by recominant human erythropoietin.  Blood. 1991;  78 2564-2567
    PubMedGoogle Scholar
  • 27 Chott A, Gisslinger H, Thiele J et al.. Interferon-alpha induced morphological changes of megakaryocytes: a histomorphological study on bone marrow biopsies in chronic myeloproliferative disorders with excess thrombocytoses.  Br J Haematol. 1990;  74 10-16
    PubMedGoogle Scholar
  • 28 Wang O, Miyakawa Y, Fox N et al.. Interferon-α directly represses megakaryopoiesis by inhibiting thrombopoietin-induced signaling through induction of SOCS-1.  Blood. 2000;  96 2093-2099
    PubMedGoogle Scholar
  • 29 Sinzinger H, Linkesch W, Ludwig H et al.. Impaired conversion of exogenous arachidonic and by platelets to thromboxane b2 and correction of that deficiency by interferon-alpha.  Prostaglandins. 1990;  40 351-360
    CrossrefPubMedGoogle Scholar
  • 30 Martyre M C. TGF-beta and megakaryocytes in the pathogenesis of myelofibrosis in myeloproliferative disorders.  Leuk Lymphoma. 1995;  20 39-44
    PubMedGoogle Scholar
  • 31 Le Bousse-Kerdiles M C, Martyre M C. Involvement of the fibrogenic cytokines, TGF-beta and bFGF, in the pathogenesis of idiopathic myelofibrosis.  Pathol Biol (Paris). 2001;  49 153-157
    CrossrefPubMedGoogle Scholar
  • 32 Martyre M C, Magdelenat H, Calvo F. Interferon gamma in vivo reverses the increased platelet levels of platelet-derived growth factors in transforming growth factor-13 in patients with myelofibrosis with myeloid metaplasia.  Br J Haematol. 1991;  77 431-435
    PubMedGoogle Scholar
  • 33 Michiels J J, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia polycythemia vera and idiopathic myelofibrosis (agnogenic myeloid metaplasia).  Int J Hematol. 2002;  76 133-145
    PubMedGoogle Scholar
  • 34 Silver R T, Woolf S H, Hehlmann R et al.. An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.  Blood. 1999;  94 1515-1516
    PubMedGoogle Scholar
  • 35 Ellis J, Silver R T, Coleman M et al.. The bone marrow in polycythemia vera.  Semin Hematol. 1975;  12 433-444
    PubMedGoogle Scholar
  • 36 Michiels J J, Thiele J. Clinical and pathological criteria for the diagnosis of essential thrombocythemia, polycythemia vera and idiopathic myelofibrosis (agnogenic myeloid metaplasia).  Int J Haemat. 2002;  76 133-145
    PubMedGoogle Scholar
  • 37 Jones A, Silver R T, Waghorn K et al.. Minimal molecular response in polycythemia vera patents treated with imatinib or interferon alpha.  Blood. 2006;  107 3339-3341
    CrossrefPubMedGoogle Scholar
  • 38 Poncz M. BACH and the megakaryocyte symphony.  Blood. 2005;  105 3001-3002
    CrossrefPubMedGoogle Scholar

Richard T SilverM.D. 

Division of Hematology-Oncology, New York Presbyterian-Weill Cornell Medical Center

525 E. 68th Street, Box 581, New York, NY 10021-4873

Email: rsilve@med.cornell.edu

      >